DIRS.INFO The most relevant business & tech news

☆ Study links accelerated aging to cancer risk in younger adults
▼ + stars: | 2024-04-07 | by ( Brenda Goodman | ) edition.cnn.com time to read: +6 min

CNN —Researchers looking for clues about why some types of cancer are on the rise in younger adults say they’ve found an interesting lead: a connection to accelerated biological aging. What faster aging could tell us about cancer riskAfter adjusting the data for factors they thought might bias their results, the researchers found that accelerated aging was associated with increased risk for cancer. “There are medications that also look like they can slow down accelerated aging,” said Blaes, who is testing two of them in cancer survivors. Cancer survivors often show greater biological aging, perhaps because of the after effects of therapies like chemotherapy and radiation. It’s not quite prime time, where we would go out and prescribe those medications for people, but this is really, really important work,” Blaes said.

Persons: they’ve, It’s, ”, Yin Cao, Louis, Cao, Tian, ” Cao, Anne Blaes, “, Blaes, Dr, Sanjay Gupta, ” Blaes Organizations: CNN, Washington University School of Medicine, American Association of Cancer, University of Minnesota, Hematology, Oncology, UM, CNN Health, Cancer Locations: St, San Diego

☆ Pfizer is betting big on cancer drugs to turn business around after Covid decline – here's what to know
▼ + stars: | 2024-03-10 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +13 min

Now, the company is betting on cancer drugs to help it regain its footing after a rocky year marked by the rapid decline of its Covid business. That $43 billion Seagen acquisition doubled Pfizer's oncology drug pipeline to 60 different experimental programs. Some analysts noted that it might take a few years for some of Pfizer's cancer drugs in mid-stage development to show pivotal clinical trial data and become less risky. Revenue from the blockbuster breast cancer drug Ibrance and prostate cancer treatment Xtandi, which Pfizer shares with Astellas Pharma, has declined over the past year. They are among the most expensive prescription drugs in the U.S. Before the Seagen deal, 94% of Pfizer's cancer products were small-molecule drugs.

Persons: Wall, Seagen, Chris Boshoff, Boshoff, David Ryder, Trung Huynh, Joe Biden's, Chris Schott, Suneet Varma, RemeGe, Merck, Padcev, Guggenheim, Pfizer's, Pfizer hasn't, Dr, Mikael Dolsten, Irfan Khan Organizations: Nurphoto, Getty, Pfizer, Astellas Pharma, Guggenheim, Bloomberg, UBS, Medicare, Drug Administration, FDA, ADC, JPMorgan, Drugs, CNBC, CVS Pharmacy, Los Angeles Times Locations: Covid, Bothell , Washington, U.S, biologics, China, Eagle Rock , California

☆ Goldman gives this innovative cancer-fighting biotech nearly 70% upside
▼ + stars: | 2024-02-01 | by ( Hakyung Kim | ) www.cnbc.com time to read: +1 min

Biotech company Arvinas could see its shares rally from a potential medium- to long-term commercial opportunity, according to Goldman Sachs. The firm initiated coverage on Arvinas with a buy rating and price target of $70. That suggests 68.7% upside potential from where shares closed Wednesday. According to analyst Paul Choi, breast cancer drug vepdegestrant (ARV-471), which is being co-developed by Arvinas and Pfizer , presents an "underappreciated" commercial opportunity. Arvinas has a "differentiated protein degrader platform that could expand several major markets," Choi wrote in a Thursday note.

Persons: Goldman Sachs, Paul Choi, Arvinas, Choi, — CNBC's Michael Bloom Organizations: Biotech, Arvinas, Pfizer

☆ Long-distance caregiving meant flying 600 miles to my mom every 3 weeks. It showed me family bonds transcend all.
▼ + stars: | 2024-02-01 | by ( Tiffany Drummond | ) www.businessinsider.com time to read: +5 min

At the time, I was living almost 600 miles away, but wanted to be her caregiver. download the app Email address Sign up By clicking “Sign Up”, you accept our Terms of Service and Privacy Policy . It was the day an ambulance rushed my mother to the hospital — and the day "cancer" became a routine topic of conversation in our household. I wanted to be my mother's caregiver but lived 600 miles awayThe care team developed a treatment plan that included monthly rounds of chemotherapy and radiation. Almost 600 miles separated my parents' home in coastal North Carolina from my Brooklyn apartment.

Persons: —, Tiffany Drummond's Organizations: Service Locations: North Carolina, Brooklyn, New York

☆ Iron deficiency could be making millions of Americans tired. 5 foods high in iron, from meat to produce, could help fix it.
▼ + stars: | 2023-11-27 | by ( Kate Hull | ) www.businessinsider.com time to read: +5 min

Alexander Spatari/ Getty ImagesIron comes in two different forms: heme iron and nonheme iron. Animal products contain heme iron, which comes from hemoglobin — a protein responsible for transporting oxygen in blood. Roughly 25 to 30 percent of heme iron is absorbed by your body, according to a 2019 study . However, these foods contain nonheme iron — a type of iron that is not as readily absorbed by the body. Witthaya Prasongsin/ Getty ImagesWhite beans are a good source of nonheme iron: A 1-cup serving of canned white beans contains 8 mg of nonheme iron .

Persons: —, Alexander Spatari, Prasongsin, it's Organizations: Service, American Society of Hematology, National Institutes of Health, Consumer

☆ Was This a Recurrence of Non-Hodgkin’s Lymphoma or Something Else?
▼ + stars: | 2023-11-20 | by ( Lisa Sanders | ) www.nytimes.com time to read: +3 min

He introduced himself and asked the patient to tell his story, listening as the man described his trip, his weakness, his rash, his fever. Kaminski asked if he had any body aches. On the ride home, his neck felt strangely weak, as if his head had suddenly gotten much heavier. He had felt this sick only once in his life — and that time was diagnosed with lymphoma. As he examined the priest, Kaminski noted that his rash was on his back and arms as well as his chest.

Persons: Martin Kaminski, Kaminski, hadn’t Organizations: Beth Israel Deaconess Medical Locations: South America

☆ Goldman says this biotech could become a global cell therapy leader, has nearly 40% upside
▼ + stars: | 2023-11-06 | by ( Alex Harring | ) www.cnbc.com time to read: +1 min

Legend Biotech has a best-in-class product and could become a global leader in the cell and gene therapy space, according to Goldman Sachs. "We believe Legend has the potential to grow into a leading global cell therapy company," Chen said in a note to clients. Its leading therapy in the space is Carvykti, which he described as "best-in-class." In partnership with Johnson & Johnson , Carvykti is undergoing capacity expansion in the U.S. and European Union to meet demand. Legend stock rose 0.3% in Monday's session.

Persons: Goldman Sachs, Ziyi Chen, Chen, Johnson, Carvykti, — CNBC's Michael Bloom Organizations: Biotech, Johnson, Union Locations: U.S

☆ Here are Friday's biggest analyst calls: Netflix, Nvidia, Eli Lilly, Disney, Levi's, Exxon, Walmart and more
▼ + stars: | 2023-10-06 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

JPMorgan reiterates Exxon as overweight JPMorgan said it's standing by its buy rating on the oil and gas giant. Seaport initiates Netflix as buy Seaport said it sees plenty of upside in shares of Netflix. JPMorgan upgrades Eaton to overweight from neutral JPMorgan said the industrial and electrical company is best in class. UBS reiterates Levi's as buy UBS said Levi's is still an attractive stock despite the company's disappointing earnings report Thursday. " JPMorgan upgrades Apellis to overweight from neutral JPMorgan said the pharmaceutical company is well-positioned for more upside.

Persons: Piper Sandler, Bernstein, Disney, XOM, Jefferies, TD Cowen, Cowen, Eaton, Eli Lilly, Doug McMillon, Berenberg, Morgan Stanley, Meta, Levi's, Oppenheimer downgrades O'Reilly, AutoZone, Oppenheimer, it's, Truist Organizations: Disney, Netflix, Hulu, JPMorgan, Exxon, Barclays, Nvidia, Intel, Gaudi, Citi, Discover Citi, DFS, Seaport, Bank of America, Energy, of America, Apple, Vegas, Prix, Clearway Energy, Walmart, United Auto Workers, Auto, Meta, UBS Locations: Parks, NVDA, China, ETN, TEL, AZO, ORLY

☆ Gilead Sciences could jump nearly 30% as biopharma bounces back, says Bank of America
▼ + stars: | 2023-09-08 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

The biopharmaceutical sector is poised to bounce back this year, and Gilead Sciences could be a key beneficiary, according to Bank of America. Analyst Geoff Meacham upgraded Gilead to buy from neutral. He increased his target price for the stock by $7 to $95, which suggests shares stand to gain 28.5% from where they closed Thursday. Shares of California-based Gilead have dropped 13.9% so far this year. "With the potential for broader interest in the sector, we are more optimistic on performance into 2H23," Meacham said.

Persons: Geoff Meacham, Meacham, biopharma, — Michael Bloom Organizations: Gilead Sciences, Bank of America, PrEP, Kite Pharma Locations: Gilead, California, HCV

☆ Drug shortages’ effects on cancer research may be felt for years to come
▼ + stars: | 2023-07-20 | by ( Jen Christensen | ) edition.cnn.com time to read: +8 min

But these shortages aren’t just bad for current patients, experts say; their effects on cancer research may be felt for years to come. The National Cancer Institute, the federal government’s main agency for cancer research and training, told CNN that at least 174 of its own trials may be affected by the shortages. Cisplatin and other platinum-based drugs are prescribed for 10% to 20% of all cancer patients, according to the National Cancer Institute. Crucial work on hold“With drug shortages, trials have become almost like an impossible task. “These drug shortages come and go, and there’s no real rhyme or reason, and there seems to be no rhyme or reason in terms of which institutions have shortages.

Persons: Joe Biden, it’s, ’ ”, Shadia Jalal, Indiana University Melvin, Jalal, She’s, they’ve, ” Jalal, “, ”, haven’t, “ We’ve, Mark Fleury, Fleury, you’re, ” Fleury, Dmitry Walker, Merck, We’ve, ” Walker, there’s, Biden, Lawrence Feldman, ” Feldman, Feldman, Dr, Sanjay Gupta, ‘ Organizations: CNN, National Cancer Institute, American Society of Health, Cancer, Indiana University, Bren Simon Comprehensive Cancer Center, Hematology, Oncology, IU School of Medicine, Hoosier Cancer Research Network, Veterans Administration, American Cancer Society Cancer Action Network, American Cancer Society, WVU Medicine, US Food, Pharmacists, National Comprehensive Cancer Network, University of Illinois Medical Center, CNN Health Locations: United States, China, Chicago

☆ Novartis drug cuts recurrence risk by 25% in early-stage breast cancer
▼ + stars: | 2023-06-02 | by ( Ludwig Burger | ) www.reuters.com time to read: +3 min

The company on Friday said the relative risk reduction of cancer recurrence was 25.2% and that the results were broadly consistent regardless of patients' menopausal status or cancer progression status. Kisqali has been approved to treat hormone-driven breast cancer that has spread to other parts of the body, where Novartis has taken market share from Pfizer's (PFE.N) Ibrance. But that is in a subset of women who are at high risk of recurrence after surgery, typically diagnosed based on signs of cancer in the lymph nodes. Here, Novartis will face tough competition because the U.S. drugmaker has said Verzenio reduces the risk of recurrence by 35% in that group. Novartis will request approval for wider use in the U.S. and Europe before the end of the year, it added.

Persons: Kisqali, Eli Lilly, Verzenio, drugmaker, Eli Lilly's Verzenio, Jeff Legos, Vas, Ludwig Burger, Sriraj Organizations: Novartis, American Society of Clinical Oncology, Oncology, Hematology, Thomson Locations: FRANKFURT, Chicago, U.S, Europe

☆ Drug cuts risk of breast cancer recurrence for some early-stage patients, trial shows
▼ + stars: | 2023-06-02 | by ( Jen Christensen | ) edition.cnn.com time to read: +6 min

CNN —A drug used in people in the early stage of the most common kind of breast cancer – HR+/HER2- breast cancer – significantly reduced the risk of the cancer returning after treatment, according to a new study. HR+/HER2- breast cancer has tested positive for progesterone and estrogen receptors and negative for HER2. Endocrine therapy generally works well, but for patients with HR+ or HER- breast cancer, there’s still a 10% to 40% chance that the cancer will come back, some studies show. The new trial found that when Kisqali is added to endocrine therapy, it reduces the risk of recurrence by 25% across a broad population of patients with early breast cancer. About 90% of patients who have breast cancer are diagnosed in the early stages.

Persons: there’s, Kisqali, ”, Dennis J, Slamon, Sara Tolaney, ” Tolaney, Anupama Goel, Goel, Dr, Sanjay Gupta, Alberto Montero, ” Montero, Montero Organizations: CNN, US Food and Drug Administration, American Society of Clinical Oncology, Novartis, UCLA, Comprehensive Cancer Center, Oncology, Dana, Farber Cancer Institute, Mount Sinai Tisch Cancer Center, CNN Health, UH Seidman Cancer Center, Case Western Reserve University School of Medicine Locations: Chicago, Ohio, –

☆ Why Was This Patient Turning So Yellow?
▼ + stars: | 2023-05-16 | by ( Lisa Sanders | ) www.nytimes.com time to read: +4 min

The color came from a buildup of something known as bilirubin, a breakdown product of red blood cells. Normally there is a constant low level of this dark-colored waste created and disposed of as red blood cells are born and die. The whites of a patient’s eyes might be a little yellow — it’s where jaundice is most easily seen — but this man was visibly yellow everywhere. Usually you see that only with a severe iron deficiency or with some anomaly in the shape of the red blood cells. Red blood cells with any other shape are destroyed at a much higher rate.

☆ Buy these cheap, defensive stocks as long as recession fears keep mounting, UBS says
▼ + stars: | 2023-05-02 | by ( Sarah Min | ) www.cnbc.com time to read: +2 min

As recession fears keep flaring up again on Wall Street, investors can find safety in cheap, dependable, defensive stocks, according to UBS. The UBS playbook advises investors to stick to defensive stocks rather than the types of cyclical companies stocks that have benefited from high inflation. To be sure, investors have worried that defensive stocks have grown too expensive. But UBS pointed to several defensive groups that remain cheap, including telecom and insurance. Given this backdrop, here are some of UBS' cheap defensive stocks.

Citi is bullish on Merck , saying that the company's drug pipeline is underappreciated by the market. The exclusive license and collaboration agreement for ADC development helps Merck in developing more cancer treatment drugs — and Citi thinks it could rival its competitors' offerings. Citi anticipates further upside for Merck shares from the Inflation Reduction Act. To be sure, Baum noted a key downside risk to his valuation is if the ADC pipeline disappoints. Further risks include lower-than-anticipated value share capture by the company's Melanoma treatment drug Keytruda, and a slowdown in its animal health business.

Takeda CFO Costa Saroukos in a 2018 picture. Mr. Saroukos joined Takeda in 2015 as CFO of Takeda’s European and Canadian operations before he was elevated to global CFO in 2018. WSJ: What did you learn from your deal-integration experiences that helped with the Takeda and Shire integration? ” — Costa Saroukos, CFO of TakedaAnother reason speed is important is to avoid losing talent. We broadened CFOinUrpocket to be used globally across 80 countries for the combined Takeda and Shire offices.

☆ Morgan Stanley sees this gene therapy stock doubling from here
▼ + stars: | 2023-02-01 | by ( Alex Harring | ) www.cnbc.com time to read: +2 min

Rocket Pharmaceuticals could soar as a trial with blockbuster sales potential enters a pivotal phase, according to Morgan Stanley. Analyst Michael Ulz initiated the stock at overweight with a $45 price target. That target share price implies the stock will rally 107.1% from Tuesday's close. Ulz called Rocket a "leading gene therapy company" that can find the best treatments for a given disease. RP-A501, a one-time gene therapy treatment, has shown "promising" phase one results among adults and children, Ulz said.

☆ They Caught the Seattle Market on the Way Down, but Could They Afford a House There?
▼ + stars: | 2022-11-10 | by ( Anna Kodé | ) www.nytimes.com time to read: +2 min

Lauren Held and Kyle Frederick didn’t think they could afford to own a home anytime soon, especially in Seattle’s pricey housing market. “It seemed way too competitive, with way too much tech money all around us,” she said. So the couple, both North Carolina natives, started casually hunting for a house to buy, hoping something would work out. “But we were still seeing multiple offers.”They wanted to stay in north Seattle, preferably in an area like Phinney Ridge. The pandemic market was cooling, but homes in north Seattle were still going for over asking price.

☆ Staff shortages make patient surges harder for children’s hospitals – and the situation won’t get better soon
▼ + stars: | 2022-10-28 | by ( Jen Christensen | ) edition.cnn.com time to read: +8 min

“We’re extremely overwhelmed,” said Dr. Rishi Lulla, director of pediatric hematology/oncology at Hasbro Children’s Hospital in Providence, Rhode Island. Seasonal respiratory viruses fill children’s hospitals every year, but the number of beds that are full now is well above the average. Driving much of the current need for beds at children’s hospitals is a spike in cases of RSV, which are 60% higher than at 2021’s peak. Nurse turnover is up 50% across the country since 2019, according to Mark Wietecha, CEO of the Children’s Hospital Association. Get CNN Health's weekly newsletter Sign up here to get The Results Are In with Dr. Sanjay Gupta every Tuesday from the CNN Health team.

Register now for FREE unlimited access to Reuters.com RegisterSwiss drugmaker Novartis' logo is seen at the company's plant in the northern Swiss town of Stein, Switzerland October 23, 2017. Register now for FREE unlimited access to Reuters.com RegisterIt ranked 10th in the U.S. market last year, the company added. Novartis also said it would focus in future on five areas for investment: cardiovascular, immunology, neuroscience, solid tumors and hematology medicine. The company last month said it planned to spin off Sandoz to sharpen its focus on its patented prescription medicines. Register now for FREE unlimited access to Reuters.com RegisterEditing by Mark Potter and Jason NeelyOur Standards: The Thomson Reuters Trust Principles.

Search resuls for: "Hematology"

20 mentions found